XRCC1 and lung carcinoma: The XRCC1 Arg194Trp polymorphism was not significantly associated with the median PFS of advanced lung cancer patients treated with platinum-based chemotherapy (TrpTrp vs. ArgArg: HR = 1.01, 95% CI, 0.69–1.48, P = 0.948, Fig. 2C; TrpArg vs. ArgArg: HR = 1.06, 95% CI, 0.82–1.36, P = 0.662; TrpTrp+TrpArg vs. ArgArg: HR = 1.05, 95% CI, 0.79–1.38, P = 0.753, Table 3).